tiprankstipranks
Korro Bio, Inc. (KRRO)
NASDAQ:KRRO
US Market
KRRO
Korro Bio
RESEARCH TOOLSreports
Want to see KRRO full AI Analyst Report?

Korro Bio (KRRO) Stock Forecast & Price Target

571 Followers
See the Price Targets and Ratings of:

KRRO Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Korro
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KRRO Stock 12 Month Forecast

Average Price Target

$19.00
▲(32.04% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Korro Bio in the last 3 months. The average price target is $19.00 with a high forecast of $30.00 and a low forecast of $10.00. The average price target represents a 32.04% change from the last price of $14.39.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","14":"$14","24":"$24","34":"$34","44":"$44"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,14,24,34,44],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.37,11.879999999999999,13.39,14.9,16.41,17.92,19.43,20.94,22.450000000000003,23.96,25.47,26.980000000000004,28.490000000000002,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.37,11.033846153846152,11.697692307692307,12.36153846153846,13.025384615384615,13.689230769230768,14.353076923076923,15.016923076923076,15.68076923076923,16.344615384615384,17.00846153846154,17.67230769230769,18.336153846153845,{"y":19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.37,10.34153846153846,10.313076923076922,10.284615384615384,10.256153846153845,10.227692307692307,10.199230769230768,10.170769230769231,10.142307692307693,10.113846153846154,10.085384615384616,10.056923076923077,10.028461538461539,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.65,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.57,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.93,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.65,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.37,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$19.00Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on KRRO
Unknown Analyst
LifeSci Capital
Not Ranked
LifeSci Capital
$21
Buy
45.93%
Upside
Reiterated
08/07/26
Buy Rating Reiterated on Strong Pipeline Progress and Clinical Catalysts; $21 Price Target Unchanged
Piper Sandler Analyst forecast on KRRO
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$30
Buy
108.48%
Upside
Reiterated
08/07/26
Piper Sandler Keeps Their Buy Rating on Korro Bio (KRRO)
H.C. Wainwright Analyst forecast on KRRO
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$15
Buy
4.24%
Upside
Reiterated
08/07/26
Korro Bio Retains Buy Rating as Advancing RNA Editing Pipeline and Strong Cash Runway Support Unchanged $15 Price Target
Clear Street Analyst forecast on KRRO
William Maughan
Clear Street
Clear Street
$18
Buy
25.09%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)
RBC Capital Analyst forecast on KRRO
Luca Issi
RBC Capital
RBC Capital
$10
Hold
-30.51%
Downside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (NASDAQ: CRBP) and Korro Bio (NASDAQ: KRRO)
William Blair Analyst forecast on KRRO
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analyst Reaffirms Buy on Korro Bio, Citing Undervalued OPERA RNA Editing Platform and Multi-Billion-Dollar Pipeline Potential
Cantor Fitzgerald Analyst forecast on KRRO
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$22
Buy
52.88%
Upside
Reiterated
08/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Korro Bio (NASDAQ: KRRO), Electrocore (NASDAQ: ECOR) and BioLife Solutions (NASDAQ: BLFS)
Chardan Capital Analyst forecast on KRRO
Keay Nakae
Chardan Capital
Chardan Capital
$15
Buy
4.24%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)
Citi Analyst forecast on KRRO
Yigal Nochomovitz
Citi
Citi
$21
Buy
45.93%
Upside
Initiated
05/18/26
Korro Bio initiated with a Buy at CitiKorro Bio initiated with a Buy at Citi
JonesTrading Analyst forecast on KRRO
Catherine Novack
JonesTrading
JonesTrading
$23
Buy
59.83%
Upside
Upgraded
05/08/26
Korro Bio upgraded to Buy from Hold at JonesResearchKorro Bio upgraded to Buy from Hold at JonesResearch
Raymond James Analyst forecast on KRRO
Ryan Deschner
Raymond James
Raymond James
$23
Buy
59.83%
Upside
Upgraded
03/13/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Bristol-Myers Squibb (NYSE: BMY)
Oppenheimer Analyst forecast on KRRO
Kostas Biliouris
Oppenheimer
Oppenheimer
$22
Buy
52.88%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (NASDAQ: SLDB), Korro Bio (NASDAQ: KRRO) and Pharming Group (NASDAQ: PHAR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on KRRO
Unknown Analyst
LifeSci Capital
Not Ranked
LifeSci Capital
$21
Buy
45.93%
Upside
Reiterated
08/07/26
Buy Rating Reiterated on Strong Pipeline Progress and Clinical Catalysts; $21 Price Target Unchanged
Piper Sandler Analyst forecast on KRRO
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$30
Buy
108.48%
Upside
Reiterated
08/07/26
Piper Sandler Keeps Their Buy Rating on Korro Bio (KRRO)
H.C. Wainwright Analyst forecast on KRRO
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$15
Buy
4.24%
Upside
Reiterated
08/07/26
Korro Bio Retains Buy Rating as Advancing RNA Editing Pipeline and Strong Cash Runway Support Unchanged $15 Price Target
Clear Street Analyst forecast on KRRO
William Maughan
Clear Street
Clear Street
$18
Buy
25.09%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)
RBC Capital Analyst forecast on KRRO
Luca Issi
RBC Capital
RBC Capital
$10
Hold
-30.51%
Downside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (NASDAQ: CRBP) and Korro Bio (NASDAQ: KRRO)
William Blair Analyst forecast on KRRO
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analyst Reaffirms Buy on Korro Bio, Citing Undervalued OPERA RNA Editing Platform and Multi-Billion-Dollar Pipeline Potential
Cantor Fitzgerald Analyst forecast on KRRO
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$22
Buy
52.88%
Upside
Reiterated
08/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Korro Bio (NASDAQ: KRRO), Electrocore (NASDAQ: ECOR) and BioLife Solutions (NASDAQ: BLFS)
Chardan Capital Analyst forecast on KRRO
Keay Nakae
Chardan Capital
Chardan Capital
$15
Buy
4.24%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)
Citi Analyst forecast on KRRO
Yigal Nochomovitz
Citi
Citi
$21
Buy
45.93%
Upside
Initiated
05/18/26
Korro Bio initiated with a Buy at CitiKorro Bio initiated with a Buy at Citi
JonesTrading Analyst forecast on KRRO
Catherine Novack
JonesTrading
JonesTrading
$23
Buy
59.83%
Upside
Upgraded
05/08/26
Korro Bio upgraded to Buy from Hold at JonesResearchKorro Bio upgraded to Buy from Hold at JonesResearch
Raymond James Analyst forecast on KRRO
Ryan Deschner
Raymond James
Raymond James
$23
Buy
59.83%
Upside
Upgraded
03/13/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Bristol-Myers Squibb (NYSE: BMY)
Oppenheimer Analyst forecast on KRRO
Kostas Biliouris
Oppenheimer
Oppenheimer
$22
Buy
52.88%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (NASDAQ: SLDB), Korro Bio (NASDAQ: KRRO) and Pharming Group (NASDAQ: PHAR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Korro Bio

3 Months
Kostas BiliourisOppenheimer
Success Rate
9/16 ratings generated profit
56%
Average Return
+8.00%
Copying Kostas Biliouris's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +8.00% per trade.
1 Year
Kostas BiliourisOppenheimer
Success Rate
8/16 ratings generated profit
50%
Average Return
+11.39%
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +11.39% per trade.
2 Years
Kostas BiliourisOppenheimer
Success Rate
9/16 ratings generated profit
56%
Average Return
+25.79%
Copying Kostas Biliouris's trades and holding each position for 2 Years would result in 56.25% of your transactions generating a profit, with an average return of +25.79% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KRRO Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
9
5
5
3
Buy
4
6
3
3
4
Hold
1
2
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
17
9
9
8
In the current month, KRRO has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KRRO average Analyst price target in the past 3 months is 19.00.
Each month's total comprises the sum of three months' worth of ratings.

KRRO Financial Forecast

KRRO Earnings Forecast

Next quarter’s earnings estimate for KRRO is -$1.26 with a range of -$2.04 to -$0.93. The previous quarter’s EPS was -$1.07. KRRO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KRRO has Performed in-line its overall industry.
Next quarter’s earnings estimate for KRRO is -$1.26 with a range of -$2.04 to -$0.93. The previous quarter’s EPS was -$1.07. KRRO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KRRO has Performed in-line its overall industry.

KRRO Sales Forecast

Next quarter’s sales forecast for KRRO is $167.00K with a range of $0.00 to $1.50M. The previous quarter’s sales results were $0.00. KRRO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KRRO has Performed in-line its overall industry.
Next quarter’s sales forecast for KRRO is $167.00K with a range of $0.00 to $1.50M. The previous quarter’s sales results were $0.00. KRRO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KRRO has Performed in-line its overall industry.

KRRO Stock Forecast FAQ

What is KRRO’s average 12-month price target, according to analysts?
Based on analyst ratings, Korro Bio, Inc.’s 12-month average price target is 19.00.
    What is KRRO’s upside potential, based on the analysts’ average price target?
    Korro Bio, Inc. has 32.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KRRO a Buy, Sell or Hold?
          Korro Bio, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Korro Bio, Inc.’s price target?
            The average price target for Korro Bio, Inc. is 19.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $10.00. The average price target represents 32.04% Increase from the current price of $14.39.
              What do analysts say about Korro Bio, Inc.?
              Korro Bio, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of KRRO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.